| Not Yet Recruiting | Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatell NCT07500298 | M.D. Anderson Cancer Center | Phase 1 |
| Not Yet Recruiting | A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Ver NCT07502014 | Huazhong University of Science and Technology | Phase 2 |
| Not Yet Recruiting | ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly NCT07381764 | Gruppo Oncologico Italia Meridionale | Phase 2 |
| Not Yet Recruiting | Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients W NCT07124858 | Federation Francophone de Cancerologie Digestive | N/A |
| Not Yet Recruiting | A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. NCT07395063 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Phase 2 |
| Not Yet Recruiting | A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCA NCT07446387 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Recruiting | Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced NCT07042685 | The Methodist Hospital Research Institute | Phase 2 |
| Not Yet Recruiting | Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for NCT07286695 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Canc NCT07228832 | Summit Therapeutics | Phase 3 |
| Not Yet Recruiting | A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers NCT07233850 | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 |
| Recruiting | Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy NCT07167446 | Fox Chase Cancer Center | EARLY_Phase 1 |
| Recruiting | NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Col NCT07309289 | Shanghai Zhongshan Hospital | Phase 3 |
| Not Yet Recruiting | QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC NCT07009145 | Qianfoshan Hospital | Phase 2 |
| Recruiting | Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal C NCT06873763 | STCube, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemother NCT06944548 | Centre Georges Francois Leclerc | Phase 2 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Pa NCT06959693 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Recruiting | 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Canc NCT06887218 | The Methodist Hospital Research Institute | Phase 2 |
| Recruiting | Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MS NCT06958419 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 / Phase 3 |
| Recruiting | BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Active Not Recruiting | Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorec NCT06784947 | University of Colorado, Denver | Phase 2 |
| Not Yet Recruiting | The Study on the Efficacy and Safety of Lactobacillus Johnsonii in Combination with CapeOX and Pembrolizumab f NCT06823323 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Co NCT06856187 | Fudan University | Phase 2 |
| Recruiting | ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer NCT06825624 | Hansoh BioMedical R&D Company | Phase 1 |
| Recruiting | Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastat NCT07536113 | Niguarda Hospital | — |
| Recruiting | Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer NCT07504523 | Ying Yuan, MD | Phase 1 |
| Unknown | A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC NCT05378867 | Zhejiang Teruisi Pharmaceutical Inc. | Phase 3 |
| Terminated | A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Can NCT04627142 | Boehringer Ingelheim | Phase 1 |
| Enrolling By Invitation | Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced NCT06849362 | Yue Gou | — |